Analyst Ratings for Phathom Pharmaceuticals (PHAT)
PHAT Rating Summary
PHAT Price Target Summary
- Highest: $29.00 (Cantor Fitzgerald)
- Lowest: $12.00 (Goldman Sachs)
- Average: $23.50
* Over Last 12-Mos
Overall Rating:
BUY
Rating Trend:
Avg. $ Target:
$23.50 (+138.3%)
* Over Last 12-Mos
Rating Score: 9.2 / 10
Percentile Rank: 90%
Avg. $ Target:
$23.50 (+138.3%)
* Over Last 12-Mos
Rating Score: 9.2 / 10
Percentile Rank: 90%
| Date | Firm | Analyst | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 3/27/2026 | Barclays | Glen Santangelo | Upgrade | Overweight (Equalweight) |
18.00 (16.00) |
10.47 (9.86) |
-5.83% | Details |
| 12/12/2025 | Raymond James | Martin Auster | New Coverage | Strong Buy (N/A) |
28.00 (N/A) |
14.55 (9.86) |
-32.23% | Details |
 |
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
